{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:20:23Z","timestamp":1791559223958,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41433-025-03997-7","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:20:55Z","timestamp":1758813655000},"page":"3005-3014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravitreal faricimab for diabetic macular oedema and neovascular age-related macular degeneration: general considerations and practical recommendations by an expert panel of Italian retina specialists"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-141X","authenticated-orcid":false,"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-2488","authenticated-orcid":false,"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Mastropasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-698X","authenticated-orcid":false,"given":"Maria","family":"Vadal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-913X","authenticated-orcid":false,"given":"Francesco","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"3997_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicol\u00f2","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30:193\u2013200. https:\/\/doi.org\/10.1080\/13543784.2021.1879791.","journal-title":"Expert Opin Investig Drugs"},{"key":"3997_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","volume":"328","author":"E Fagiani","year":"2013","unstructured":"Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328:18\u201326. https:\/\/doi.org\/10.1016\/j.canlet.2012.08.018.","journal-title":"Cancer Lett"},{"key":"3997_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.277.5322.55","volume":"277","author":"PC Maisonpierre","year":"1997","unstructured":"Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55\u201360. https:\/\/doi.org\/10.1126\/science.277.5322.55.","journal-title":"Science"},{"key":"3997_CR4","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1167\/iovs.10-6386","volume":"52","author":"S Rangasamy","year":"2011","unstructured":"Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood\u2013retinal barrier in diabetic retinopathy. Invest Opthalmol Vis Sci. 2011;52:3784\u201391. https:\/\/doi.org\/10.1167\/iovs.10-6386.","journal-title":"Invest Opthalmol Vis Sci"},{"key":"3997_CR5","doi-asserted-by":"publisher","first-page":"31038","DOI":"10.1074\/jbc.M704703200","volume":"282","author":"D Yao","year":"2007","unstructured":"Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007;282:31038\u201345. https:\/\/doi.org\/10.1074\/jbc.M704703200.","journal-title":"J Biol Chem"},{"key":"3997_CR6","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.12659\/MSM.896916","volume":"22","author":"J Du","year":"2016","unstructured":"Du J, Leng J, Zhang L, Bai G, Yang D, Lin H, et al. Angiotensin II-induced apoptosis of human umbilical vein endothelial cells was inhibited by blueberry anthocyanin through bax- and caspase 3-dependent pathways. Med Sci Monit. 2016;22:3223\u20138. https:\/\/doi.org\/10.12659\/MSM.896916.","journal-title":"Med Sci Monit"},{"key":"3997_CR7","doi-asserted-by":"publisher","first-page":"H2364","DOI":"10.1152\/ajpheart.00408.2003","volume":"285","author":"V Grishko","year":"2003","unstructured":"Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol. 2003;285:H2364\u201372. https:\/\/doi.org\/10.1152\/ajpheart.00408.2003.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3997_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0002-9394(02)01323-5","volume":"133","author":"H Funatsu","year":"2002","unstructured":"Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537\u201343. https:\/\/doi.org\/10.1016\/S0002-9394(02)01323-5.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR9","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1124\/mol.105.020941","volume":"69","author":"N Umeda","year":"2006","unstructured":"Umeda N, Kachi S, Akiyama H, Zahn G, Vossmeyer D, Stragies R, et al. Suppression and regression of choroidal neovascularization by systemic administration of an \u03b1 5 \u03b2 1 integrin antagonist. Mol Pharm. 2006;69:1820\u20138. https:\/\/doi.org\/10.1124\/mol.105.020941.","journal-title":"Mol Pharm"},{"key":"3997_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, et al. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep. 2017;7:45081. https:\/\/doi.org\/10.1038\/srep45081.","journal-title":"Sci Rep"},{"key":"3997_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000339952","volume":"228","author":"M Huber","year":"2012","unstructured":"Huber M, Wachtlin J. Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization. Ophthalmologica. 2012;228:188\u201393. https:\/\/doi.org\/10.1159\/000339952.","journal-title":"Ophthalmologica"},{"key":"3997_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ajo.2004.11.064","volume":"139","author":"R Hera","year":"2005","unstructured":"Hera R, Keramidas M, Peoc\u2019h M, Mouillon M, Romanet JP, Feige JJ. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol. 2005;139:589\u201396. https:\/\/doi.org\/10.1016\/j.ajo.2004.11.064.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"},{"key":"3997_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema. Ophthalmology. 2024;131:708\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026.","journal-title":"Ophthalmology"},{"key":"3997_CR15","first-page":"2816","volume":"64","author":"RA Goldberg","year":"2023","unstructured":"Goldberg RA, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, et al. Faricimab reduces macular leakage vs aflibercept in patients with DME. Invest Ophthalmol Vis Sci. 2023;64:2816.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3997_CR16","first-page":"2089","volume":"57","author":"K Aggarwal","year":"2016","unstructured":"Aggarwal K, Agarwal A, Afridi R, Sadiq MA, Hassan M, Soliman MK, et al. Visual outcome of patients in ranibizumab for edema of the mAcula in diabetes (READ-3) study based on the characteristics of edema on optical coherence tomography. Invest Ophthalmol Vis Sci. 2016;57:2089.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3997_CR17","first-page":"4886","volume":"65","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hibar D, Maunz A, Lu H, Albrecht Y, Gibson K, et al. Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65:4886.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3997_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2:1179\u201387. https:\/\/doi.org\/10.1016\/j.oret.2018.06.004.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR19","doi-asserted-by":"publisher","unstructured":"Kuo BL, Tabano D, Garmo V, Kim E, Leng T, Hatfield M, et al. Long-term treatment patterns for diabetic macular edema. Ophthalmol Retina. 2024. https:\/\/doi.org\/10.1016\/j.oret.2024.05.017.","DOI":"10.1016\/j.oret.2024.05.017"},{"key":"3997_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","volume":"3","author":"X Gao","year":"2019","unstructured":"Gao X, Obeid A, Aderman CM, Talcott KE, Ali FS, Adam MK, et al. Loss to follow-up after intravitreal anti\u2013vascular endothelial growth factor injections in patients with diabetic macular edema. Ophthalmol Retina. 2019;3:230\u20136. https:\/\/doi.org\/10.1016\/j.oret.2018.11.002.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR21","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating wet age-related macular degeneration (TA800). Technology appraisal guidance. 2022. www.nice.org.uk\/guidance\/ta800."},{"key":"3997_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","volume":"44","author":"F Pichi","year":"2024","unstructured":"Pichi F, Abdi A, Aljneibi S, El Ghrably I, Agarwal A, Ghazi NG. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema. Int Ophthalmol. 2024;44:275. https:\/\/doi.org\/10.1007\/s10792-024-03226-2.","journal-title":"Int Ophthalmol"},{"key":"3997_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","volume":"108","author":"AF Durrani","year":"2024","unstructured":"Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, et al. Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol. 2024;108:1257\u201362. https:\/\/doi.org\/10.1136\/bjo-2023-324394.","journal-title":"Br J Ophthalmol"},{"key":"3997_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","volume":"68","author":"OA Sorour","year":"2023","unstructured":"Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68:147\u201374. https:\/\/doi.org\/10.1016\/j.survophthal.2022.11.008.","journal-title":"Surv Ophthalmol"},{"key":"3997_CR25","doi-asserted-by":"publisher","unstructured":"Radwan SH, Soliman AZ, Tokarev J, Zhang L, Van Kuijk FJ, Koozekanani DD. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol. 2015. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.0972.","DOI":"10.1001\/jamaophthalmol.2015.0972"},{"key":"3997_CR26","doi-asserted-by":"publisher","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2350.","DOI":"10.1001\/jamaophthalmol.2014.2350"},{"key":"3997_CR27","doi-asserted-by":"publisher","unstructured":"Borrelli E, Grosso D, Barresi C, Lari G, Sacconi R, Senni C, et al. Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy. Am J Ophthalmol. 2021. https:\/\/doi.org\/10.1016\/J.AJO.2021.09.002.","DOI":"10.1016\/J.AJO.2021.09.002"},{"key":"3997_CR28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"key":"3997_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology"},{"key":"3997_CR30","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE. Ophthalmol Sci. 2021;1:100076. https:\/\/doi.org\/10.1016\/j.xops.2021.100076.","journal-title":"Ophthalmol Sci"},{"key":"3997_CR31","unstructured":"Lai T, Michels S, Demetriades AM, Quezada-Ruiz C, Silverman D, Ives J, et al. Faricimab in neovascular age-related macular degeneration: 48-week results by dosing interval cohort in the phase 3 TENAYA and LUCERNE trials. Presented at the American Association of Ophthalmology Annual Meeting; Chicago (IL); 2022."},{"key":"3997_CR32","unstructured":"Vabysmo 120\u2009mg\/mL solution for injection [Summary of product characteristics]. Roche Products Limited, UK; 2022."},{"key":"3997_CR33","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, Khanani AM, Do DV, Patel H, et al. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina. 2021;41:1579\u201386. https:\/\/doi.org\/10.1097\/IAE.0000000000003194.","journal-title":"Retina"},{"key":"3997_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/IAE.0000000000003261","volume":"42","author":"A Sharma","year":"2022","unstructured":"Sharma A, Cheung CMG, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, et al. Fluid-based visual prognostication in type 3 macular neovascularization-flip-3 study. Retina. 2022;42:107\u201313. https:\/\/doi.org\/10.1097\/IAE.0000000000003261.","journal-title":"Retina"},{"key":"3997_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2019;126:252\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.035.","journal-title":"Ophthalmology"},{"key":"3997_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007.","journal-title":"Prog Retin Eye Res"},{"key":"3997_CR37","doi-asserted-by":"publisher","unstructured":"Borrelli E, Vigan\u00f2 C, Battista M, Sacconi R, Senni C, Querques L, et al. Individual vs. combined imaging modalities for diagnosing neovascular central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2022. https:\/\/doi.org\/10.1007\/s00417-022-05924-y.","DOI":"10.1007\/s00417-022-05924-y"},{"key":"3997_CR38","first-page":"5690","volume":"65","author":"N London","year":"2024","unstructured":"London N, Khanani AM, Lai TYY, Lim JI, Kotecha A, Margaron P, et al. Greater reduction in pigment epithelial detachment size in TENAYA\/LUCERNE with faricimab 6.0\u2009mg vs aflibercept 2.0\u2009mg during head-to-head dosing in patients with nAMD. Invest Ophthalmol Vis Sci. 2024;65:5690.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3997_CR39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti\u2013vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138:1043\u201351. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3001.","journal-title":"JAMA Ophthalmol"},{"key":"3997_CR40","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983\u201390. https:\/\/doi.org\/10.1038\/s41433-020-01354-4.","journal-title":"Eye"},{"key":"3997_CR41","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","volume":"121","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database. Ophthalmology. 2014;121:1966\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.026.","journal-title":"Ophthalmology"},{"key":"3997_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/aos.12610","volume":"93","author":"F van Asten","year":"2015","unstructured":"van Asten F, Evers-Birkenkamp KU, van Lith-Verhoeven JJ, de Jong-Hesse Y, Hoppenreijs VP, Hommersom RF, et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93:126\u201333. https:\/\/doi.org\/10.1111\/aos.12610.","journal-title":"Acta Ophthalmol"},{"key":"3997_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","volume":"123","author":"JS Talks","year":"2016","unstructured":"Talks JS, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N, et al. First-year visual acuity outcomes of providing aflibercept according to the VIEW Study Protocol for age-related macular degeneration. Ophthalmology. 2016;123:337\u201343. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.039.","journal-title":"Ophthalmology"},{"key":"3997_CR44","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/IAE.0000000000000548","volume":"35","author":"EH Souied","year":"2015","unstructured":"Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. Retina. 2015;35:1743\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000000548.","journal-title":"Retina"},{"key":"3997_CR45","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","volume":"120","author":"A Rasmussen","year":"2013","unstructured":"Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, LaCour M, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:2630\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2013.05.018.","journal-title":"Ophthalmology"},{"key":"3997_CR46","doi-asserted-by":"publisher","unstructured":"Rakic J-M, Leys A, Bri\u00e9 H, Denhaerynck K, Pacheco C, Vancayzeele S, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013:1849. https:\/\/doi.org\/10.2147\/OPTH.S49385.","DOI":"10.2147\/OPTH.S49385"},{"key":"3997_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","volume":"155","author":"M Kr\u00fcger Falk","year":"2013","unstructured":"Kr\u00fcger Falk M, Kemp H, S\u00f8rensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155:89\u201395.e3. https:\/\/doi.org\/10.1016\/j.ajo.2012.06.031.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327.","journal-title":"Br J Ophthalmol"},{"key":"3997_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L, Ac\u00f3n D, Berrocal MH, Diaz-Llopis M, et al. Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2016;36:859\u201367. https:\/\/doi.org\/10.1097\/IAE.0000000000000827.","journal-title":"Retina"},{"key":"3997_CR50","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","volume":"33","author":"SY Cohen","year":"2013","unstructured":"Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quer\u00e9 S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. Retina. 2013;33:474\u201381. https:\/\/doi.org\/10.1097\/IAE.0b013e31827b6324.","journal-title":"Retina"},{"key":"3997_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retina. 2020;4:19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR52","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2:645\u201353. https:\/\/doi.org\/10.1016\/j.oret.2018.01.006.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR53","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/s41433-023-02409-y","volume":"37","author":"S Sivaprasad","year":"2023","unstructured":"Sivaprasad S, Ghanchi F, Kelly SP, Kotagiri A, Talks J, Scanlon P, et al. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes. Eye. 2023;37:2753\u201360. https:\/\/doi.org\/10.1038\/s41433-023-02409-y.","journal-title":"Eye"},{"key":"3997_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40123-021-00350-5","volume":"10","author":"J Carrasco","year":"2021","unstructured":"Carrasco J, Daien V, Eldem BM, Spoorendonk JA, Yoon J. 2-year real-world outcomes with intravitreal aflibercept in neovascular age-related macular degeneration: literature review and meta-analysis of patient-relevant outcomes. Ophthalmol Ther. 2021;10:397\u2013411. https:\/\/doi.org\/10.1007\/s40123-021-00350-5.","journal-title":"Ophthalmol Ther"},{"key":"3997_CR55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","volume":"210","author":"M Gillies","year":"2020","unstructured":"Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, et al. Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions. Am J Ophthalmol. 2020;210:116\u201324. https:\/\/doi.org\/10.1016\/j.ajo.2019.10.007.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR56","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:1837\u201345. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.010.","journal-title":"Ophthalmology"},{"key":"3997_CR57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","volume":"157","author":"NM Holekamp","year":"2014","unstructured":"Holekamp NM, Liu Y, Yeh WS, Chia Y, Kiss S, Almony A, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157:825\u201333.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.12.018.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128:234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060.","journal-title":"Ophthalmology"},{"key":"3997_CR59","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","volume":"8","author":"C Boudousq","year":"2024","unstructured":"Boudousq C, Nguyen V, Hunt A, Gillies M, Zarranz-Ventura J, O'Toole L, et al. European unmet needs in the management of neovascular age-related macular degeneration in daily practice. Ophthalmol Retina. 2024;8:527\u201336. https:\/\/doi.org\/10.1016\/j.oret.2024.01.004.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, Adam MK, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti\u2013vascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136:1251\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3578.","journal-title":"JAMA Ophthalmol"},{"key":"3997_CR61","doi-asserted-by":"publisher","unstructured":"Borrelli E, Olivieri C, Serafino S, Coletto A, Ricardi F, Neri G, et al. Inter-reader and inter-modality variability in macular atrophy quantification in neovascular AMD: comparison of six imaging modalities. Ophthalmol Retina. 2024. https:\/\/doi.org\/10.1016\/j.oret.2024.08.017.","DOI":"10.1016\/j.oret.2024.08.017"},{"key":"3997_CR62","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.oret.2022.11.002","volume":"7","author":"G Staurenghi","year":"2023","unstructured":"Staurenghi G, Cozzi M, Sadda S, Hill L, Gune S. Characteristics that correlate with macular atrophy in ranibizumab-treated patients with neovascular age-related macular degeneration. Ophthalmol Retina. 2023;7:300\u20136. https:\/\/doi.org\/10.1016\/j.oret.2022.11.002.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR63","unstructured":"NICE Guideline. Age-related macular degeneration. 2018. https:\/\/www.nice.org.uk\/guidance\/ng82\/resources\/agerelated-macular-degeneration-pdf-1837691334853."},{"key":"3997_CR64","unstructured":"NICE Guideline, No. 82. Age-related macular degeneration: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018. https:\/\/www.nice.org.uk\/guidance\/ng82\/resources\/agerelated-macular-degeneration-pdf-1837691334853."},{"key":"3997_CR65","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8:537\u201344. https:\/\/doi.org\/10.1016\/j.oret.2023.11.015.","journal-title":"Ophthalmol Retina"},{"key":"3997_CR66","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:2153\u201362. https:\/\/doi.org\/10.1007\/s00417-024-06421-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3997_CR67","doi-asserted-by":"publisher","unstructured":"Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, et al. YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2021;2:100111. https:\/\/doi.org\/10.1016\/j.xops.2021.100111.","DOI":"10.1016\/j.xops.2021.100111"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03997-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:06:15Z","timestamp":1762171575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03997-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":67,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3997"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03997-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EB is a member of the Eye editorial board. EB: AbbVie; Bayer; Espansione; EyePoint; Novartis; Ocular Therapeutix; Hofmann La Roche; Zeiss. FB: Abbvie, Alcon, Bayer, Hofmann La Roche. PL: Adverum, Aerie, Abbvie, Annexon, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyebio, Eyepoint Pharmaceuticals, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Hofmann La Roche. ML: Abbvie, Apellis, Bayer, Novartis, Hofmann La Roche, Heidelberg Engineering. RM: None. MN: None. MP: Abbvie, Novartis, Bayer, Hofmann La Roche, Zeiss. FR: Abbvie, Apellis, Astellas, Bayer, Genetech, MS&D, Novartis, Regeneron, Hofmann La Roche. GS: Abbvie, Apellis Pharmaceuticals, Inc., Annexon Bioscience, Bayer Healthcare Pharmaceuticals, Boehringer, Centervue, Inc., Genentech, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Medscape, Novartis Pharmaceuticals, Optos, Inc., and RetinAI. MV: Abbvie, Novartis, Bayer, Hofmann La Roche, Zeiss. FV: None. SV: Abbvie, Adverum, Alimera, Annexon, Apellis, Bayer, Boehringer & Ingelheim, Novartis, Roche, Zeiss. FB: Abbvie, Alimera, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, Ntc Pharma, Oxurion Nv, Sifi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}